# A Novel Protein Delivery System for Therapy of Preeclampsia

> **NIH NIH R01** · UNIVERSITY OF MISSISSIPPI MED CTR · 2020 · $492,157

## Abstract

Abstract.
 Preeclampsia is a common hypertensive disorder of pregnancy and is one of the leading causes of maternal,
fetal, and perinatal morbidity and mortality. Affecting ~8% of all pregnancies in the US, preeclampsia displays
characteristic hypertension, proteinuria, and altered cardiovascular function and, if left unchecked, can lead to
maternal seizures and death. There is currently no effective intervention for preeclampsia short of induced
delivery of the fetus, which is why it is also a leading cause of premature birth. Improvements in preeclampsia
management have been largely stifled due to deleterious effects of various proposed small molecule therapeutics
on the developing fetus. The objective of the proposed studies is to develop a drug delivery system capable of
stabilizing novel therapeutic agents in the maternal circulation while protecting them from entering the fetal
circulation. The onset and progression of preeclampsia is driven by two major pathways, secretion of the VEGF
antagonist sFlt-1 and induction of a highly inflammatory environment in the mother. We have developed novel
agents targeting each of these pathways, a supplementary VEGF therapy to counteract the increased sFlt-1
levels and NF-κB inhibitory peptide therapy to block the inflammatory response. These therapeutics are attached
to a drug delivery vector called elastin-like polypeptide (ELP) that stabilizes them in the maternal circulation while
preventing them from crossing the placenta into the fetal circulation. During the first funding period, we assessed
the therapeutic potential of one agent from each class, ELP fusion to VEGF-A121 to counteract sFlt-1 and an ELP
fusion to a peptide that blocks NF-kB nuclear import to counteract the inflammatory signaling. We confirmed the
activity of both agents in vitro, measured their in vivo pharmacokinetics and confirmed that ELP fusion prevents
their placental transfer, and demonstrated their therapeutic efficacy in a rat model of preeclampsia. While both
agents were effective in the rat model, we believe that each may be improved. For the ELP-fused VEGF, we
hypothesize that a different, less angiogenic form of VEGF (VEGF-B167), will have more potent sFlt-1 binding
while inducing less aberrant angiogenesis, thus making it a safer therapeutic option. For the NF-kB inhibitory
peptides, we have generated five new peptides that target the NF-kB activation cascade a different levels, and
we hypothesize that one (or a combination of multiple) of these peptides will have a more potent anti-
inflammatory effect. During the renewal period, we will evaluate our second-generation agents in vitro to confirm
their target binding and mechanism of action, assess their safety, pharmacokinetics, and therapeutic efficacy in
our rat model of placental ischemia, and, in order to advance our lead agents toward translation, assess their
safety and efficacy in a novel non-human primate model of gestational hypertension, the African Green Monk...

## Key facts

- **NIH application ID:** 9973513
- **Project number:** 2R01HL121527-06
- **Recipient organization:** UNIVERSITY OF MISSISSIPPI MED CTR
- **Principal Investigator:** Gene Leflore Bidwell
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $492,157
- **Award type:** 2
- **Project period:** 2014-01-15 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9973513

## Citation

> US National Institutes of Health, RePORTER application 9973513, A Novel Protein Delivery System for Therapy of Preeclampsia (2R01HL121527-06). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9973513. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*